Search Results

Apex Labs Ltd. (APEX or the Company) is pleased to announce the filing of an IND application with the U.S. Food and Drug Administration (FDA) for APEX-002-B01-02, a pioneering pharmacokinetics and driving simulator study of APEX-52 take home microdose psilocybin.

Wellbeing Digital Sciences Inc. will participate in Microdose’s Psychedelic Capital: September 2022 Conference to be held virtually on September 29, 2022 at 1:30 p.m. ET.

Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, showcased the Microdose Array Print Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8.

MindBio Therapeutics Corp. demonstrates how 1 million microdoses of LSD could potentially benefit tens of thousands of patients with Depression.

MindBio Therapeutics Corp. is pleased to have started pre-screening for participant entry into Phase 2 LSD-Microdosing clinical trials.

Apex Labs Ltd. (APEX or the Company) is pleased to announce the completion of the first-ever take home microdose psilocybin clinical trial, meeting all endpoints over a two month period with no adverse events.